Drug class
RAS(ON) multi-selective inhibitor; targeted antineoplastic small molecule
Mechanism of action
Inhibits active GTP-bound RAS G12X and wild-type RAS signalling across multiple RAS isoforms, suppressing downstream MAPK pathway signalling in RAS-driven tumours.
General use cases
- Treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy under the US FDA RASONQUE indication approved 26 August 2026
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
